Effect of olezarsen on routinely measured lipase and amylase levels in familial chylomicronemia syndrome
Journal of Clinical Lipidology · 2025
DOI: 10.1016/j.jacl.2025.05.007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Veronica J Alexander und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ionis Pharmaceuticals, Inc., USA (Drs Alexander, Prohaska, Karwatowska-Prokopczuk, Xia, and Tsimikas). Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type I, Lipase, Amylases. Die Arbeit nennt 18 Literaturangaben. Gefördert von: European Commission, Ionis Pharmaceuticals.
Abstract (Originalsprache)
BACKGROUND: Olezarsen reduces acute pancreatitis events in patients with familial chylomicronemia syndrome (FCS). Lipase and amylase are biomarkers of acute pancreatitis released by the pancreas. OBJECTIVE: To assess whether routinely measured plasma levels of lipase and amylase are modified by treatment with olezarsen in patients with FCS. METHODS: Lipase and amylase were measured at baseline, and days 85, 169, 253, and 365 in patients randomly assigned to placebo, olezarsen 50 mg and 80 mg monthly for 365 days in the Balance trial. RESULTS: Compared to placebo, significant differences were present in lipase levels in olezarsen 80 mg at days 85 (P = .026), 169 (P = .036) and 253 (P = .036) with a trend at day 365 (P = .096). Average percent change from baseline from day 1 to day 365 revealed a mean (SD) percent increase in lipase of 12.6% (32.4) in placebo, a 6.7% (45.4) increase in olezarsen 50 mg (P = .26 vs placebo) and a reduction of -10.4% (22.7) in olezarsen 80 mg (P = .035 vs placebo) groups. In patients without a reported adverse event of abdominal pain, the placebo group showed a mean percent increase in lipase ranging from 7.91% to 39.1% from day 1 to day 365, olezarsen 50 mg -8.47% to 24.0%, and olezarsen 80 mg -15.4% to -29.6%, leading to significant differences at day 85 (P = .014), day 169 (P = .028), day 253 (P = .008), and day 365 (P = .045) (P-values vs placebo). Changes in amylase mirrored changes in lipase but did not reach statistical significance. CONCLUSION: Changes in routinely measured lipase levels may reflect subclinical pancreatic injury. Olezarsen favorably modifies changes in lipase in patients with FCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ionis Pharmaceuticals, Inc., USA (Drs Alexander, Prohaska, Karwatowska-Prokopczuk, Xia, and Tsimikas).
- Ionis Pharmaceuticals, Inc., USA (Drs Alexander, Prohaska, Karwatowska-Prokopczuk, Xia, and Tsimikas); University of California San Diego, USA (Dr Tsimikas). Electronic address: stsimikas@health.ucsd.edu.
Förderung
- European Commission
- Ionis Pharmaceuticals
Zitieren
APA
Alexander, V. J., Prohaska, T. A., Karwatowska-Prokopczuk, E., Xia, S., & Tsimikas, S. (2025). Effect of olezarsen on routinely measured lipase and amylase levels in familial chylomicronemia syndrome. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.05.007
Vancouver
Alexander VJ, Prohaska TA, Karwatowska-Prokopczuk E, Xia S, Tsimikas S. Effect of olezarsen on routinely measured lipase and amylase levels in familial chylomicronemia syndrome. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.05.007
BibTeX
@article{Alexander2025,
author = {Alexander, Veronica J and Prohaska, Thomas A and Karwatowska-Prokopczuk, Ewa and Xia, Shuting and Tsimikas, Sotirios},
title = {Effect of olezarsen on routinely measured lipase and amylase levels in familial chylomicronemia syndrome},
journal = {Journal of Clinical Lipidology},
year = {2025},
doi = {10.1016/j.jacl.2025.05.007}
}
EUVIMED